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Abstract
Background: Retarded wound healing in patients with obesity contributes to a risk of complications associated
with vascular insufficiency and oxidative stress. The high cholesterol levels of patients with obesity are associated
with apoptosis of engrafted umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs). Melatonin
contributes to the prevention of cholesterol accumulation in patients with obesity via a mechanism that is poorly
understood. We therefore investigated the regulatory mechanism of melatonin in cholesterol-induced apoptosis.
Methods: The protective effects of melatonin on cholesterol-induced apoptosis were investigated in UCB-MSCs. We
used a mouse model of induced obesity to show that melatonin treatment restored the survival rate of
transplanted UCB-MSCs and their wound-healing capacity. The mean values of the treatment groups were
compared with those of the control group using Student’s t test, and differences among three or more groups
were analyzed using one-way analysis of variance with Dunnett’s multiple comparison test.
Results: Melatonin treatment increased the expression of ATP-binding cassette subfamily A member 1 (ABCA1),
which reduced cholesterol accumulation and cholesterol-induced apoptosis. The mouse skin wound healing model
showed that melatonin treatment restored the survival rate of transplanted UCB-MSCs and the wound-healing
capacity of obese mice. Melatonin inhibited the expression of binding immunoglobulin protein (BiP) through the
regulation of MT2/Sp1-dependent microRNA-597-5p. Melatonin decreased the co-localization of BiP with nuclear
factor erythroid 2-related factor 1 (NRF1), which resulted in increased ABCA1 expression.
Conclusion: Melatonin induced the efflux of intracellular cholesterol through ABCA1 to decrease apoptosis of UCB-
MSCs via an MT2-dependent BiP/NRF1 pathway.
Keywords: Mesenchymal stem cells, Cholesterol efflux, Nuclear factor erythroid 2-related factor 1, Stem cell
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Background
The endogenous indoleamine hormone melatonin (N-
acetyl-5-methoxytryptamine) is synthesized and secreted
by many organs, including the pineal gland, which regu-
lates the day/night sleep cycle [1]. Melatonin regulates
physiological processes in cells, including regulation of
oxidative stress, cell migration, and apoptosis [2]. More-
over, melatonin and cholesterol levels are associated with
obesity [3], and melatonin decreases cholesterol absorp-
tion and accumulation in rats [4]. Furthermore, melatonin
inhibits the activation of sterol regulatory element-binding
transcription factor 1c, fatty acid synthase, and stearoyl-
CoA desaturase 1-associated lipogenesis and increases
peroxisome proliferator-activated receptor-α-dependent
lipolysis [5, 6]. However, the mechanism by which mela-
tonin regulates the efflux of intracellular cholesterol is
unknown.
Nuclear factor erythroid 2-related factor 1 (NRF1, also
known as NFE2L1) is required to maintain cholesterol
homeostasis via repression of ATP-binding cassette
subfamily A member 1 (ABCA1) expression [7]. NRF1, a
member of the cap‘n’colar basic leucine zipper family, is
present on the endoplasmic reticulum (ER) membrane,
and the nuclear translocation of NRF1 is stringently reg-
ulated by HMG-CoA reductase degradation 1 (HRD1)-
dependent ER-associated degradation (ERAD) [8]. The
cholesterol recognition/interaction amino acid consensus
sequence domain of NRF1 directly binds to cholesterol in
the ER membrane, which influences the suppression of
HRD1-dependent ERAD and nuclear translocation of
NRF1 [7]. The substrate of ERAD is recognized by pro-
teins such as binding immunoglobulin protein (BiP), OS9
ER lectin, and store-operated calcium entry-associated
regulatory factors. These proteins bind to protein sel-1
homolog 1, the core of the HRD1 complex, to transfer the
substrate to HRD1 [9]. Elevated cholesterol levels lead to
downregulation of NRF1 ubiquitination and degradation
through ERAD to achieve cholesterol efflux, although the
detailed mechanism by which cholesterol regulates ERAD
processing of NRF1 remains poorly understood [7]. More-
over, melatonin increases ERAD gene expression (Hrd1,
Vcp, and Os9), leading to the suppression of tunicamycin-
induced ER stress as well as senescence [10]. These find-
ings indicate that melatonin regulates ERAD-dependent
NRF1 translocation, which mediates the efflux of choles-
terol present at high levels.
Clinical reports indicate that the wound healing
process in some patients with obesity is extremely slow,
contributing to a higher risk of infection and diminished
quality of life [11]. Furthermore, metabolic diseases such
as obesity increase the production of reactive oxygen
species (ROS), and consequently, induce a delay in
vasculogenesis, granulation, and re-epithelialization of
wound sites [12]. To manipulate obesity-related wounds,
multiple promising therapies using stem cells are cur-
rently under investigation. Umbilical cord blood-derived
mesenchymal stem cells (UCB-MSCs) have low immun-
ity and immunomodulatory effects, thereby increasing
the survival of transplanted cells and decreasing the risk
of graft-versus-host disease [13]. Furthermore, UCB-
MSCs are widely used to accelerate tissue regeneration
because of their ability to self-renew, mediate the para-
crine effects of immunomodulatory and vasculogenic
cytokines, and differentiate into diverse cell lineages
[14]. However, the therapeutic efficacy of stem cell
transplantation for the treatment of patients with obesity
accompanied by hyperlipidemia and hypercholesterol-
emia is lower than that achieved for treating patients
without obese [15, 16]. High levels of circulating cholesterol
increase its intracellular levels, and excess cholesterol in-
duces ER stress, production of NADPH oxidase-dependent
ROS, and oxidative stress of sufficient intensity to cause cell
death [17]. Furthermore, the cholesterol transporter is
closely associated with the levels of intracellular cholesterol
and ROS as well as apoptosis when cells are exposed to
high cholesterol concentrations [18]. Considering that
excessive levels of intracellular cholesterol increases cell
death and that melatonin regulates cholesterol levels, exam-
ining the cholesterol regulatory mechanism of melatonin
can suggest the possibility of improved therapeutic effects
of UCB-MSCs for treating skin wound healing in patients
with obesity. For this purpose, we investigated UCB-MSCs
in vivo and in vitro to identify the regulatory mechanism




UCB-MSCs were acquired from Kang Stem Biotech
(Seoul, Korea). Fetal bovine serum (FBS) and antibiotics
were purchased from Hyclone (Logan, UT, USA) and
Gibco (Grand Island, NY, USA), respectively. 4-P-PDOT
(#SML1189), cholesterol (#C4951), DIDS (#D3514),
melatonin (#M5250), and Ver155008 (#SML0271) were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Mithramycin A (#1489) was purchased from Tocris
(Minneapolis, MN, USA). Antibodies against ABCA1
(#ab18180), α-SMA (#ab5694), and Sp1 (#ab227383)
were purchased from Abcam (Cambridge, England) and
against HSF1 (#H00003297-A01) were purchased from
Abnova (Taipei, Taiwan). Antibodies against NRF1
(#8052S) and cleaved-caspase 3 (#9661) were purchased
from Cell Signaling Technology (Beverly, MA, USA),
and those against BiP (#MA5-27686) and phospho-Sp1
(Thr453, #PA5-38333) were purchased from Invitrogen
(Carlsbad, CA, USA). Antibodies against MT1 (#NBP1-
71113) were purchased from Novus Biologicals (Little-
ton, CO, USA). Antibodies against β-actin (#sc-47778),
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caspase 9 (#sc-8355), lamin A/C (#sc-20681), and MT2
(#sc-28453) were purchased from Santa Cruz Biotech-
nology (Dallas, TX, USA). All primers for mRNA and
miRNA were purchased from Cosmogenetech (Seoul,
Korea). Small interfering RNAs (siRNAs) were pur-
chased from Bioneer (Deajeon, Korea).
Cell culture
UCB-MSCs were cultured with α-minimum essential
medium (α-MEM; Hyclone, #SH30265.01) containing
10% FBS and 1% antibiotics at 37 °C in an atmosphere
containing 5% CO2. Cells cultured to 80% confluency
were incubated with serum-free α-MEM for 24 h before
treatment with reagents.
Cholesterol quantification assay
Cells were harvested, and cholesterol was extracted with
200 μL of chloroform:isopropanol:NP40 (7:11:0.1) solu-
tion. After spin down at maximum speed to remove
debris, the supernatant was transferred to new tubes and
dried at 50 °C for 4 h. The pellets were resolved in assay
buffer and incubated with enzyme-mixed assay buffer at
37 °C for 30 min. The absorbance at 570 nm was mea-
sured using a microplate spectrophotometer (Epoch 2™;
BioTek, Winooski, VT, USA).
Western blot analysis
The collected cells were lysed with RIPA lysis buffer
(Atto, Tokyo, Japan, #AE6500). Samples were prepared
using sample buffer, loaded into 8–12% sodium dodecyl
sulfate–polyacrylamide gels, and transferred to polyviny-
lidene fluoride membranes. The membranes were
washed with tris-buffered saline containing 0.2% Tween-
20 (TBST) (10 min, three times) and blocked with 5%
skim milk in TBST at room temperature (RT) for 30
min. After incubation with a primary antibody solution
in TBST (1:2000 dilution) at 4 °C overnight, the mem-
branes were incubated with anti-mouse or rabbit horse-
radish peroxidase-conjugated secondary antibody solution
at RT for 2 h. The β-actin band was used as a loading
control. Collected images of bands were analyzed using
ImageJ software.
Immunocytochemistry analysis
UCB-MSCs were cultured in confocal dishes (SPL,
Pocheon, Korea, #200350), fixed with 70% acetone in
PBS for 10 min, and then permeabilized with 0.1%
TritonX-100 in PBS for 10 min. After blocking with 5%
normal goat serum (NGS) in PBS solution for 30 min,
cells were incubated with primary antibodies in 5% NGS
solution (1:100 dilution) at 4 °C overnight and with
secondary antibodies in 5% NGS solution (1:200 dilution) at
RT for 2 h. The cells were visualized using a super-resolution
radial fluctuation imaging system (Andor Technology, UK).
The relative fluorescence intensities of nuclear NRF1 and
total NRF1 or co-localization of NRF1 and BiP were quanti-
fied using Fiji software.
Transfection of siRNAs or microRNA mimics
For transfection, NRF1 siRNAs or microRNA-597 (miR-597)
mimics (25 nM) were incubated with TurboFect™ transfec-
tion reagent (Thermo Fisher, #R0531) and transfected to
UCB-MSCs for 24 h. The sequences of the siRNAs and
microRNA mimics used are presented in Supplementary
Table 1.
Quantitative polymerase chain reaction for analyzing
mRNA and microRNA expressions
Total RNA samples were extracted using RNA extrac-
tion kits (Takara, Otsu, Shiga, Japan, #9767). Then, 1 μg of
RNA was reverse-transcribed into cDNA using reverse
transcription-PCR premix (iNtRON Biotechnology, Seong-
nam, Korea, #25081). The cDNA samples of mRNA were
amplified using TB™ Green Premix (Takara, #RR420A) and
primers for the target RNAs. The relative expression levels
of mRNAs and microRNAs were quantified using 2−ΔΔCt
analysis. The primer sequences are presented in
Supplementary Table 2.
MicroRNA microarray
Biotinylated RNA strands were hybridized at 48 °C for
18 h on an Affymetrix GeneChip miRNA 4.0 Array
(Affymetrix, Santa Clara, CA, US). The arrays were
analyzed using an Affymetrix GeneChip scanner with
associated software. The miRNA expression levels were
calculated using Transcriptome Analysis Console. Rela-
tive signal intensities were generated for each miRNA
using the Robust Multi Array Average algorithm. The
microarray data were analyzed using a row z-score.
Annexin V-FITC/PI staining
UCB-MSCs (1 × 105 cells) were detached from the
culture dishes, and collected cells were suspended in
binding buffer. Annexin V-FITC and PI (BD Bioscience,
Franklin Lakes, NJ, USA, #556547) were added to the
samples, and the samples were incubated for 15 min at
RT. The apoptotic cells were measured and analyzed
using flow cytometry (CytoFlex; Beckman Coulter,
Fullerton, CA, USA). Annexin V-FITC-positive and PI-
positive (Q2) and Annexin V-FITC-positive and PI-negative
(Q4) cells were considered to have undergone apoptosis.
Water-soluble tetrazolium salt (WST-1) cell viability assay
After washing with PBS, cells were incubated in 10% EZ-
Cytox™ (Daeil Lab service, Korea, #EZ-1000) solution in
100 μL of medium at 37 °C for 30 min. The absorbance
at 450 nm was then measured using a microplate
spectrophotometer (Epoch 2™, BioTek).
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Trypan blue exclusion assay
UCB-MSCs were washed with PBS, detached, and spun
down at 3000 rpm. The cell pellet was suspended with
0.4% trypan blue (Sigma–Aldrich, #T6146) in PBS to
stain dead cells. The number of trypan blue-stained and
blue-unstained cells was counted using a Countess II FL
Automated Cell Counter (Thermo Fisher).
Measurements of intracellular ROS
The cells were washed with PBS and incubated in 1 mM
CM-H2DCFDA (Thermo Fisher, #C6821) in culture
media at 37 °C for 30 min. The fluorescence intensity of
CM-H2DCFDA was measured using a luminometer at
excitation and emission wavelengths of 485 and 535 nm.
Mouse skin wound healing model
A high-fat diet (HFD, 60 kcal% fat, Research Diets Inc.,
NJ, USA) was provided to 6-week-old male Institute of
Cancer Research (ICR) mice for 14 weeks. All mice were
anesthetized with a mixture of Alfaxan™ (80 mg/kg,
Jurox Pty Ltd., Rutheford, Australia) and xylazine HCl
(10 mg/kg, Rompun™, Bayer, Leverkusen, Germany). The
backs of anesthetized mice were shaved and scrubbed
with organic iodine solution and 70% ethanol solution
for disinfection during surgery. A wound was made in
the back skin using a 6-mm-diameter circular biopsy
punch. Then, 1 × 106 UCB-MSCs were injected intrader-
mally at three sites around each wound. Intraperitoneal
injection of melatonin was conducted (30 mg/kg/day) for
12 days after wound formation. All mice were sacrificed
at post-injection day 12. A serum biochemistry instru-
ment was used to measure total cholesterol levels. The
skin samples were fixed with 4% paraformaldehyde
(PFA) and dehydrated with 20% and 30% sucrose
solutions. Dehydrated skin samples were embedded in
optimum cutting temperature compound (Sakura Fine-
tek, CA, USA, #4583) and stored at − 80 °C. Frozen skin
samples were cut into 20-μm-thick sections and
mounted on silane-coated slides.
Hematoxylin and eosin (H&E) staining
Skin tissue samples were mounted on slides, fixed with
4% PFA for 5 min, and then stained with H&E for 5 min.
Samples were washed with 70%, 95%, and 100% ethanol
three times and then incubated in xylene for 5 min. All
images were acquired using the Eclipse Ts2™ fluores-
cence microscope (Nikon, Tokyo, Japan). Histological
evaluations were performed blindly.
Immunohistochemistry
Skin samples on slides were fixed in 80% acetone
solution for 20 min. Slides were washed in PBS and incu-
bated in 5% NGS for 30 min. Samples were incubated
with the primary antibody in PBS containing 0.2%
Tween-20 (PBST) for 2 h. After incubating with second-
ary antibodies in PBST (1:100 dilution) for 1 h, images
were acquired using the Eclipse Ts2™ fluorescence
microscope.
Statistical analysis
Statistical analysis and graphing were performed using
GraphPad Prism version 6.0 (GraphPad Inc., San Diego,
CA, USA) statistical software. The mean values of treat-
ment groups were compared with those of the control
group using the Student’s t test, and differences among
three or more experimental groups were analyzed using
one-way analysis of variance with Dunnett’s multiple
comparison test. p < 0.05 was considered statistically
significant.
Results
Effect of melatonin on ABCA1-induced cholesterol efflux
in the presence of high cholesterol concentrations
On measuring apoptosis of UCB-MSCs treated with
different concentrations of cholesterol (0–200 μM), we
found that 200 μM cholesterol significantly reduced the
survival of UCB-MSCs after 24 h (Fig. 1a, b). Cholesterol
efflux depends on a membrane transporter and, there-
fore, we determined changes in the expression levels of
genes encoding cholesterol transporters. The ABCA1
mRNA level was significantly increased in UCB-MSCs
(Fig. 1c). Western blot results showed that the ABCA1
protein level also increased (Fig. 1d). We next used the
ABCA1 inhibitor DIDS (10 μM) to determine the role of
ABCA1 in the regulation of intracellular cholesterol
levels. DIDS treatment followed by the addition of chol-
esterol significantly increased the levels of intracellular
cholesterol compared with cholesterol treatment alone
(Fig. 1e). Western blot results showed that melatonin
and cholesterol treatment further increased ABCA1
expression compared with cholesterol treatment alone
(Fig. 1f). Cells were pretreated with DIDS or melatonin,
and the intracellular cholesterol level was measured to
determine the relationship between melatonin-induced
ABCA1 expression and the regulation of intracellular
cholesterol levels. High concentrations of cholesterol
added to the cultures increased the intracellular choles-
terol levels, which were decreased when the cells were
pretreated with melatonin. However, combined treat-
ment with melatonin and DIDS did not significantly
increase cholesterol levels when cells were pretreated
with DIDS. These results indicate that ABCA1 is
required to regulate the action of melatonin on intracel-
lular cholesterol levels (Fig. 1g). Collectively, the levels of
ABCA1 were increased when cells were treated with
high concentrations of cholesterol, and melatonin
increased ABCA1 levels and cholesterol efflux.
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Effects of melatonin on high cholesterol-induced
intracellular ROS levels and apoptosis
To evaluate the correlation between high cholesterol
levels and apoptosis, we measured cholesterol-induced
ROS. Cholesterol treatment significantly increased ROS
levels, which were further increased when cells were pre-
treated with DIDS (Fig. 2a). The effects of cholesterol on
apoptotic cell death were assessed using western blot
and Annexin V/PI assays. The expression levels of
caspase 9 and caspase 3 and the percentages of cell
death were significantly increased following cholesterol
treatment, and DIDS treatment further increased the
level of apoptosis of cholesterol-treated cells (Fig. 2b, c).
Cells were treated with cholesterol combined with DIDS
or melatonin to determine the effect of melatonin on
cholesterol-induced ROS levels and the involvement of
ABCA1-dependent regulation of cholesterol efflux.
Melatonin significantly decreased cholesterol-induced
ROS, and combined treatment with DIDS and melatonin
did not significantly change ROS levels compared with
that in cells pretreated with DIDS (Fig. 2d). Western blot
analysis showed that melatonin decreased cholesterol-in-
duced caspase 9 and caspase 3 expression levels (Fig. 2e).



























































Fig. 1 Effects of melatonin on ABCA1 expression and intracellular cholesterol level under high cholesterol condition. a, b UCB-MSCs were treated
with various concentrations and time and then viability was measured by trypan blue exclusion assay (n = 5). c, d UCB-MSCs were treated with
200 μM cholesterol for 24 h. c The expression levels of cholesterol transporter genes (ABCA1, ABCG1, ABCG5, and ABCG8) were measured by qPCR
(n = 5). d The expression level of ABCA1 was quantified by western blot assay and relative optical density was measured by ImageJ (n = 5). e UCB-
MSCs were pretreated with DIDS (10 μM) for 30 min prior to cholesterol treatment (200 μM, 24 h) and cellular cholesterol level was measured by
cholesterol quantification kit (n = 5). f Melatonin (1 μM) was pretreated for 30 min before cholesterol treatment (200 μM, 24 h) and the expression
level of ABCA1 was measured by western blotting (n = 5). g UCB-MSCs were pretreated with DIDS or melatonin prior to cholesterol treatment
and their total cholesterol levels were measured by quantification kit (n = 5). All blot images are representative and quantitative data are
presented as a mean ± standard error of the mean. *p < 0.05 vs control, #p < 0.05 vs cholesterol, $p < 0.05 vs melatonin + cholesterol
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restored the viability of cholesterol-treated cells to the
control level. There was no significant difference between
treatment with DIDS before exposure to cholesterol and
treatment with cholesterol combined with DIDS and
melatonin (Fig. 2f). Thus, melatonin alleviated the effects
of cholesterol-induced ROS and apoptosis through choles-
terol efflux mediated by increased ABCA1 expression.
Effect of melatonin on the therapeutic efficacy of transplanted
UCB-MSCs in a mouse model of HFD-induced obesity
Obesity was induced in mice by feeding them HFD for
14 weeks to determine the effect of melatonin on UCB-
MSCs transplanted into skin wounds. The mice had
higher weight and total cholesterol levels than mice fed
normal diet (ND) (Fig. 3a, b). To determine the
difference between the efficacy of UCB-MSC transplant-
ation into obese and normal mice, we used a skin wound
healing model. On day 12 after causing the skin injury,
the transplantation efficacy was compared by measuring
the sizes of wound closures. The wound sizes of UCB-
MSC-transplanted HFD mice were significantly larger
than that of UCB-MSC-transplanted ND mice. Mela-
tonin restored the wound sizes in UCB-MSC-
transplanted HFD mice to those in UCB-MSC-
transplanted ND mice. However, in mice transplanted
with DIDS-pretreated UCB-MSC cells, melatonin did
not show the enhancing wound healing effect of UCB-
MSC (Fig. 3c). The effect of UCB-MSCs on vasculogen-
esis was recovered by melatonin treatment, which was





















































Fig. 2 Effects of melatonin on high cholesterol-induced ROS accumulation and apoptosis. a–c UCB-MSCs were pretreated with DIDS (10 μM) prior
to cholesterol treatment (200 μM, 24 h). a The intracellular ROS level was measured by CM-H2DCFDA. The relative fluorescence units (RFU) was
measured by luminometer (n = 5). b The expression level of caspase 9 and 3 were quantified by western blotting (n = 5). c The percentage of
apoptosis was analyzed with Annexin V/PI assay. Annexin V-FITC-positive and PI-positive (Q2), and Annexin V-FITC-positive and PI-negative (Q4)
UCB-MSCs were considered as apoptotic (n = 5). d The cells were pretreated with melatonin (1 μM) or DIDS (10 μM) prior to cholesterol treatment
(200 μM, 24 h), and the level of total ROS was measured by CM-H2DCFDA (n = 5). e The cells were pretreated with melatonin (1 μM) prior to
cholesterol treatment (200 μM, 24 h) and then the expression levels of caspase 9 and 3 were measured by western blotting (n = 5). f The cells
were pretreated with melatonin (1 μM) or DIDS (10 μM) prior to cholesterol treatment (200 μM, 24 h), and cell viability was measured with WST-1
assay (n = 5). All blot images are representative and quantitative data are presented as a mean ± standard error of the mean. *p < 0.05 vs control,
#p < 0.05 vs cholesterol, $p < 0.05 vs melatonin + cholesterol, n.s. means not significant
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antiapoptotic effect of melatonin on engrafted UCB-
MSCs, we measured human nuclear antigen expression
in wounded tissues. Melatonin-treated HFD mice har-
bored the same number of UCB-MSCs as transplanted
ND mice, which decreased when the cells were pre-
treated with DIDS (Fig. 3e). Histological scores for re-
epithelialization indicated that melatonin treatment in-
creased the extent of re-epithelialization in UCB-MSC-
transplanted mice compared with that in other HFD
mice (Fig. 3f). Furthermore, we measured the level of fi-
brosis to evaluate the efficacy of wound healing therapy
with Masson trichrome staining and immunohistochem-
istry using α-SMA antibody. The results showed that fi-
brosis in granulation tissues increased with melatonin
treatment, whereas inhibition of ABCA1 in UCB-MSCs































































































































































Fig. 3 Effects of melatonin on transplanted cells in the HFD-induced obese mouse model. Obese mouse model was prepared by feeding high-
fat-diet (HFD) for 14 weeks. a, b Weight and the level of total cholesterol in serum of HFD-induced obese mice were compared with normal diet
(ND) feeding mice (n = 7, *p < 0.05 vs ND). Mice were divided into the 8 groups and skin wound healing model was conducted. After making
wounds on the skin of the back, UCB-MSCs with or without DIDS pretreatment were inoculated near the wound site and melatonin (30 mg/kg/
day) was injected to the mice of melatonin treatment group. c, d Wound size and vasculogenesis around the wound site were observed (n = 7,
*p < 0.05 vs ND + vehicle, #p < 0.05 vs HFD + UCB-MSC, $p < 0.05 vs HFD + UCB-MSC +melatonin). e Immunohistochemistry (IHC) was conducted
with an antibody for human nuclear antigen (HNA, green) and DAPI (blue) staining and visualized by fluorescence microscopy. Scale bars were
set as 100 μm (magnification × 100). The percentage of HNA-positive cells in total cells were analyzed with Fiji software (n = 5, *p < 0.05 vs ND +
UCB-MSC, #p < 0.05 vs HFD + UCB-MSC, $p < 0.05 vs HFD + UCB-MSC +melatonin, N.D. indicates not detected). f H&E staining was conducted on
tissues of wound site and compared. Scale bars are 200 μm (magnification × 50). D dermis, E epidermis, G granulation tissue. g Masson’s
trichrome staining was conducted on skin wound tissues. Scale bars are 100 μm (magnification × 100) h IHC was conducted with an antibody for
alpha-smooth muscle antigen (α-SMA, green) and DAPI (blue) staining. Scale bars were set as 200 μm (magnification × 50), (n = 5, *p < 0.05 vs
ND + UCB-MSC, #p < 0.05 vs HFD + UCB-MSC, $p < 0.05 vs HFD + UCB-MSC +melatonin). All images are representative and quantitative data are
presented as a mean ± standard error of the mean
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of MSC transplantation for mice with obesity was im-
proved by the ABCA1-dependent effects of melatonin.
Role of MT2-dependent BiP/NRF1 inhibition of melatonin-
induced ABCA1 expression
We determined the levels of mRNAs and proteins of
melatonin receptors 1A and 1B using qPCR and western
blotting; the MT2 mRNA and protein expression level
were increased in cholesterol-treated UCB-MSCs (Fig. 4a,
b). NRF1 regulates cholesterol homeostasis by repressing
the activity of LXRα, which is a major transcription factor
that drives the expression of ABCA1. Furthermore, ERAD
regulates the nuclear translocation of NRF1. Therefore, we
determined the melatonin-dependent changes in the
mRNA expression of ERAD-related proteins under


























































Fig. 4 Involvement of MT2/Bip/NRF1 pathway in melatonin-induced ABCA1 expression. a and b Cholesterol (200 μM, 24 h) was treated to UCB-MSCs
and the changes in expression levels of MT1 and MT2 were measured by qPCR or western blotting (n = 5, *p < 0.05 vs control). c Melatonin (1 μM) was
pretreated to UCB-MSCs before cholesterol treatment (200 μM, 24 h) and then the expression levels of HSPA5, DERLIN, HERP, SEL1L, and VCP were
compared by qPCR (n = 5, *p < 0.05 vs cholesterol). d MT2 inhibitor, 4-P-PDOT (10 μM) were pretreated prior to melatonin treatment (1 μM) and the
expression level of BiP was measured by western blotting (n = 5, *p < 0.05 vs control, #p < 0.05 vs cholesterol + melatonin). e Immunocytochemistry
was conducted with NRF1 (green) and BiP (red) specific antibodies and DAPI (blue) and then visualized by SRRF imaging system. Scale bar was set as
8 μm (magnification × 1000) (n = 5, *p < 0.05 vs control, #p < 0.05 vs cholesterol). f, g NRF1 or NT siRNA was transfected to UCB-MSCs using transfection
reagents prior to cholesterol treatment (200 μM, 24 h). The expression levels of ABCA1 and NRF1 were measured by western blotting and the level of
total cholesterol was quantified with cholesterol quantification kit (n = 5, *p < 0.05 vs NT siRNA, #p < 0.05 vs NT siRNA + cholesterol). All blot and
images are representative and quantitative data are presented as a mean ± standard error of the mean
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show that cholesterol treatment following melatonin treat-
ment significantly decreased the levels of HSPA5 mRNA
(Fig. 4c). We next used the competitive MT2 antagonist 4-
phenyl-2-propionamidotetralin (4-P-PDOT) to determine if
the regulatory effect of melatonin on BiP was MT2-
dependent. The western blot results show that 4-P-PDOT
treatment abolished the melatonin-induced decrease of BiP
expression (Fig. 4d). We performed immunocytochemistry
to confirm these findings. The results showed that mela-
tonin treatment further decreased the co-localization of BiP
and NRF1 and the nuclear translocation of NRF1 compared
with that in cholesterol-treated cells (Fig. 4e). To confirm
the regulatory effect of NRF1 on ABCA1 expression and
cholesterol efflux, we determined the effect of an NRF1-
specific siRNA on ABCA1 levels and intracellular choles-
terol levels in the presence of high cholesterol concentra-
tions. Under these conditions, NRF1 knockdown increased
ABCA1 levels and decreased intracellular cholesterol levels
compared with those in cells transfected with NT siRNA
(Fig. 4f, g). Thus, melatonin increased ABCA1 expression
via MT2-dependent inhibition of BiP expression and nu-
clear translocation of NRF1.
Role of BiP in the nuclear translocation of NRF1 and
ABCA1 expression in the presence of high cholesterol
concentrations
To determine the role of BiP in ERAD-dependent nu-
clear translocation of NRF1, we treated cells with the
BiP inhibitor Ver155008 (10 μM) and performed im-
munocytochemistry to detect NRF1 and BiP co-
localization as well as NRF1 nuclear translocation.
Ver155008 decreased NRF1 and BiP co-localization to
a greater extent than that in cholesterol-treated cells,
and NRF1 nuclear translocation similarly decreased
(Fig. 5a). We next determined whether decreased
NRF1 nuclear translocation caused by BiP inhibition
affected ABCA1 expression. The increase of ABCA1
levels in UCB-MSCs treated with Ver155008 and then
with cholesterol was higher than that in cells treated
with cholesterol alone (Fig. 5b). To evaluate the effect
of BiP inhibition on NRF1-dependent regulation of
the levels of intracellular cholesterol and ROS and
cholesterol-induced apoptosis, we quantified choles-
terol and ROS levels and used Annexin V/PI analyses
to measure the level of apoptosis. We found that
Ver155008 treatment followed by cholesterol treat-
ment decreased intracellular cholesterol levels, ROS
levels, and apoptosis of UCB-MSCs in the presence of
high cholesterol concentrations (Fig. 5c, d, and e).
Collectively, suppression of BiP decreased NRF1 nu-
clear translocation, which increased the levels of
ABCA1 and decreased the levels of cholesterol as well
as high-cholesterol-induced apoptosis.
Role of Sp1-induced miR-597 in the inhibition of BiP
expression by melatonin
We investigated the regulation of BiP expression by
melatonin via the MT2 signaling pathway. For this, we
determined if BiP expression was regulated by micro-
RNAs. Eighty-three BiP-targeting microRNAs were
selected from three databases (Genecards, microRNA.
org, and Diana tools), and we performed microRNA
microarray to select the microRNA candidates that in-
creased following melatonin treatment. The microarray
data were analyzed using row z-score with hierarchical
clustering to compare the changes in expression levels of
microRNAs, and we identified a cluster of 14 candidate
microRNAs whose expression levels were increased
following melatonin treatment (Fig. 6a). We conducted
qPCR to confirm the expression levels of candidate
microRNAs under cholesterol and melatonin conditions,
and the results showed that miR-597-5p expression was
significantly increased following melatonin treatment
(Fig. 6b). We next used a microRNA mimic to determine
whether miR-597-5p regulated BiP expression. The
qPCR and western blot results revealed that miR-597-5p
mimic suppressed BiP expression and upregulated
ABCA1 expression compared with that in cholesterol-
treated cells (Fig. 6c, d). Among transcription factors
regulated by MT2-dependent signaling pathways and
candidates that bind the miR-597 promoter region, we
selected Sp1. First, we determined if the effect of mela-
tonin on Sp1 activation was dependent on MT2. Thr453
phosphorylation of Sp1, which activates Sp1, increased
with melatonin treatment but decreased when cells were
pretreated with 4-P-PDOT. Immunocytochemistry re-
sults revealed that Sp1 nuclear translocation increased in
response to melatonin treatment, which was inhibited
when cells were pretreated with 4-P-PDOT (Fig. 6e, f).
Next, to verify the role of Sp1 in the regulation of miR-
597 expression, we pretreated cells with mithramycin A
to inhibit Sp1 activation. The results revealed that
mithramycin A decreased melatonin-induced miR-597
expression (Fig. 6g). Thus, melatonin decreased the ex-
pression of BiP via an MT2-Sp1-dependent miR-597
regulatory pathway.
Discussion
We demonstrated that melatonin protected UCB-MSCs
from cholesterol-induced apoptosis through a BiP/
NRF1-dependent intracellular cholesterol efflux mechan-
ism. In the presence of high cholesterol concentrations,
LXRα-dependent responses sense and adapt to increased
cholesterol efflux through the increased expression of
ABCA1 [19]. We showed that ABCA1 was required for
the downregulation of intracellular cholesterol levels and
cholesterol-induced apoptosis. Furthermore, increased
ABCA1 expression in the presence of high cholesterol
Kim et al. Stem Cell Research & Therapy          (2021) 12:114 Page 9 of 14
concentrations did not protect the cells from cholesterol-
induced apoptosis. A previous study showed that increas-
ing the expression levels of cholesterol transporters
upregulates cholesterol efflux, which is required for inhibit-
ing cholesterol-induced apoptosis [20]. Another study
demonstrated that ABCA1 overexpression suppresses the
accumulation of cholesterol [21]. In the present study,
melatonin treatment of UCB-MSCs reduced the levels of
high-cholesterol-induced ROS and apoptosis and intracel-
lular cholesterol levels by increasing ABCA1 expression.
As shown here and in another study, DIDS combined with
melatonin abolished cholesterol efflux mediated by
ABCA1 without significantly changing the levels of
ABCA1 or ROS [22]. The various effects of melatonin
such as lowering oxidative stress, regulating lipid
metabolism, and inducing receptor-mediated signal
transduction could be involved in protecting UCB-
MSC apoptosis under a high cholesterol environment
[23–25]. Considering that intracellular cholesterol
regulation is critical for oxidative stress, which acti-
vates numerous signaling pathways, including signal
molecules related to oxygen and lipids, our proposed
target can be of therapeutic importance. Because lipid-
mediated oxidative stress could be increased in pa-
tients with obesity and HFD mice, oxidative stress is
implicated in the pathogenesis, and it has been stud-
ied for its damaging effects [26]. We also found that
cells pretreated with Ver155008 (BiP inhibitor) de-
creased intracellular cholesterol levels, ROS, and













































Fig. 5 Role of BiP in nuclear NRF1 and ABCA1 expression under high cholesterol condition. a–e UCB-MSCs were pretreated BiP inhibitor,
Ver155008 (10 μM) prior to cholesterol treatment (200 μM, 24 h). a Immunocytochemistry was conducted with NRF1 (green), BiP (red) specific
antibodies and DAPI (blue), and then visualized by SRRF imaging system. Scale bar was set as 8 μm (magnification × 1000). The co-localization of
BiP and NRF1, nuclear translocation of NRF1 were analyzed with Fiji software. (n = 7). b The expression level of ABCA1 was quantified with
western blotting (n = 5). c The concentration of the cellular cholesterol was measured with cholesterol quantification kit (n = 5). d Cells were
incubated with CM-H2DCFDA and relative fluorescence units (RFU) were measured by luminometer (n = 5). e Cell viability was measured by
trypan blue exclusion assay (n = 5). All blot and images are representative and quantitative data are presented as a mean ± standard error of the
mean. *p < 0.05 vs control, #p < 0.05 vs cholesterol
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conditions. These findings indicate that the protective ef-
fect of melatonin on high-cholesterol-induced ROS gener-
ation and apoptosis does not require ROS scavenging but
rather inhibition of cholesterol accumulation. Therefore,
we suggest that the protective effect conferred upon stem
cells by melatonin is explained by the ABCA1-mediated















































































































































Fig. 6 Involvement of melatonin-activated Sp1/miR-597 pathway in BiP suppression. a UCB-MSCs were treated with melatonin (1 μM, 24 h) and
total RNAs were extracted. MicroRNA microarray was conducted and the expression levels of microRNAs were analyzed using hierarchical
clustering with heatmap. b A cluster of expression-increased microRNAs was selected and their expression levels under high cholesterol and
melatonin condition were analyzed by qPCR (n = 5, *p < 0.05 vs control). c, d miR-597 mimic was transfected to UCB-MSCs for 24 h prior to
cholesterol treatment (200 μM, 12 h). The mRNA expressions of HSPA5 and ABCA1 and protein expression levels of BiP and ABCA1 were quantified
with qPCR and western blotting (n = 5, *p < 0.05 vs NT mimic, #p < 0.05 vs NT mimic + cholesterol). e, f MT2 inhibitor 4-P-PDOT (10 μM) was
pretreated prior to melatonin treatment (1 μM, 12 h). e The phosphorylation of Sp1 (Thr453) were measured by western blotting (n = 5, *p < 0.05
vs control, #p < 0.05 vs melatonin). f Immunocytochemistry was conducted with Sp1 (green) specific antibody and DAPI (blue). Scale bar was set
as 8 μm (magnification × 1000, n = 5, *p < 0.05 vs control, #p < 0.05 vs melatonin). g Sp1 inhibitor Mithramycin A (5 nM) was pretreated prior to
melatonin treatment (1 μM, 12 h), and the change of expression level of miR-597-5p was assessed through qPCR (n = 5, *p < 0.05 vs control, #p <
0.05 vs melatonin). All images are representative and quantitative data are presented as a mean ± standard error of the mean
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Because of its occurrence and cost, skin wounds
represent a primary health concern, and therapeutic ap-
proaches using UCB-MSCs have been studied to acceler-
ate the wound healing process in preclinical and clinical
studies [27]. However, many reports show that the effect
of stem cell transplantation for promoting skin wound
recovery was reduced in patients with obesity [15, 16].
In obesity, impairment of skin wound recovery can lead
to tissue necrosis, which can diminish the patient’s
quality of life and lead to complications [28]. Therefore,
we conducted this study to improve the efficacy of UCB-
MSCs transplantation therapy in patients with obesity,
and the tissue regenerative effects were evaluated using
the skin wound healing model. In a mouse model of
obesity, using UCB-MSCs, we showed that melatonin
treatment improved the efficacy of stem cell transplant-
ation therapy, which was abolished following ABCA1
inhibition. Melatonin treatment did not significantly
change the levels of plasma cholesterol in the mice, and
analysis of the UCB-MSCs revealed a regulatory role that
controls intracellular cholesterol levels. Previous investi-
gations found that the administration of melatonin (10–
30mg/kg/day) for 4–8 weeks decreased total serum
levels of cholesterol in sera harvested from HFD mice
[29, 30]. In the present study, we injected melatonin (30
mg/kg/day) for 12 days after wound formation. Consist-
ent with our results, two studies found that the adminis-
tration of melatonin (4–10 mg/kg/day) for 2 weeks had
no significant effect on serum cholesterol levels [31, 32].
These differences can be attributed to the duration of
melatonin administration. When we focused on short-
term treatment, melatonin affected the regulation of
intracellular cholesterol levels in transplanted UCB-
MSCs rather than cholesterol levels in the blood. Our
study suggested that the decreased stem cell therapeutic
efficacy in obese conditions was improved by an increase
in survival rates of transplanted UCB-MSCs following
melatonin treatment, although the plasma levels of chol-
esterol in obese mice were still high, which can lead to
disease onset. Previous studies showed that melatonin
treatment increases the efficacy of transplanted UCB-
MSCs in skin wound healing experiments, whereas
melatonin enhances immunoregulatory effects and the
proliferation of adipose tissue-derived MSCs [2]. In con-
trast, we show here that inhibition of ABCA1 expression
diminished the effects of melatonin on the engraftment
rate of UCB-MSCs and skin wound healing, which indi-
cates that the regulation of intracellular cholesterol
levels by melatonin is important. A previous study found
that the increased survival rate of transplanted UCB-
MSCs was positively correlated with their regenerative
potentials, such as wound regeneration, wound closure
rate, and neovascularization [33]. Overall, the present
study showed that UCB-MSC dysfunction during UCB-
MSC transplantation into obese mice could be prevented
by treatment with melatonin. Therefore, we proposed a
melatonin co-treatment strategy to prevent a decrease in
the efficacy of UCB-MSC transplantation therapy.
We demonstrated that melatonin decreased BiP
expression through an MT2-dependent miR-597 regula-
tory pathway and that BiP was required for the nuclear
translocation of NRF1. NRF1 reportedly regulates the
antioxidant effect by increasing the transcription of anti-
oxidant response element genes [34]. In contrast, under
high cholesterol conditions, NRF1 regulates cholesterol
homeostasis in the ER membrane by decreasing nuclear
translocation and increasing ABCA1 expression [7].
Furthermore, our results showed that the decrease in
high-cholesterol-induced ROS following melatonin treat-
ment is ABCA1-dependent. Therefore, we investigated
the role of NRF1 regulation by melatonin in ABCA1
expression under cholesterol conditions. Cholesterol
treatment also increased the MT2 expression in UCB-
MSCs, and another study found that ROS accumulation
was significantly associated with MT2 expression [35].
We suggest, therefore, that high-cholesterol-induced
ROS accumulation induces MT2 expression. If true, this
process has important implications for the use of
melatonin to control the levels of intracellular choles-
terol because increased sensitivity to melatonin activates
downstream pathways in the presence of high choles-
terol levels. Evidence indicates that BiP contributes to
ERAD by selecting substrates and assembly of the ERAD
complex [36]. The ubiquitin-conjugating enzyme E2G2
together with the HRD1 complex polyubiquitinates
substrates and the valosin-containing protein p97 to
retro-transport substrates to the cytosol [37]. The ex-
pression levels and translocation of NRF1 are regulated
by ERAD, suggesting the participation of BiP in the
ERAD-dependent translocation of NRF1 [8]. Our results
are consistent with this possibility because we show that
BiP inhibition further decreased the cholesterol-induced
reduction in NRF1 nuclear translocation, leading to in-
creased ABCA1 expression. Some studies showed that
melatonin treatment reduced stress-induced BiP expres-
sion [38, 39]. Our results show that melatonin treatment
decreased the levels of HSPA5 mRNA and BiP but did
not change the expression and activation of its transcrip-
tion factor. A study showed that melatonin regulates cel-
lular physiological functions through microRNAs [40].
Further, microRNAs inhibit cancer cell proliferation and
metastasis, and melatonin-induced miR-392a and miR-
34b increase cancer cell apoptosis by inhibiting ABCB1/
ABCB4 activity [41]. Moreover, melatonin regulates the
transcription of microRNAs through the CEBP pathway
or the Sp1 pathway [42]. We, therefore, focused on the
regulatory effects of a melatonin-induced microRNA on
HSPA5 mRNA transcription. We demonstrated that
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melatonin treatment increased MT2-dependent phos-
phorylation and nuclear translocation of Sp1, which in-
duced miR-597-5p expression to inhibit BiP. To the best
of our knowledge, this is the first study to report that
melatonin induces miR-597-5p expression. Further stud-
ies are required to define the mechanism by which miR-
597 regulates BiP expression.
Conclusions
We demonstrated that melatonin rescued UCB-MSCs
from high-cholesterol-induced apoptosis by downregu-
lating the expression of BiP as well as the nuclear trans-
location of NRF1, which plays an essential role in the
regulation of intracellular cholesterol levels. This is the
first report to reveal the novel role of melatonin in intra-
cellular cholesterol efflux and the details of the under-
lying mechanism. We suggest focusing research efforts
on developing a new strategy that employs melatonin to
enhance the resistance of UCB-MSCs to high cholesterol
levels to improve the efficacy of stem cell transplantation
to treat patients with obesity.
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